Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsy 2024: Technologies & Applications

Daniel Hayes's Biography

Daniel Hayes, Stuart B. Padnos Professor of Breast Cancer Research, University of Michigan Rogel Cancer Center

Dr. Hayes received undergraduate, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Southwestern Medical School/Health Science Center/Parkland Memorial Hospital and a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI). He has led the breast cancer programs at DFCI (1991-1996), Georgetown University’s Lombardi Cancer Center (1996-2001), and the University of Michigan from 2001-2016. Dr. Hayes’ research interests are in the field of experimental therapeutics and cancer biomarkers, especially in breast cancer. His work has been particularly focused on development and validation of cancer biomarker tests, such as HER-2, CA15-3, circulating tumor cells and pharmacogenomic markers. He has been instrumental in establishing international guidelines for the use of tumor biomarker tests, including criteria for their clinical utility. He has served as chair of the SWOG Breast Cancer Translational Medicine Committee, and he was an inaugural member and chaired the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee. He has been instrumental in the joint ad hoc committees between ASCO and the College of American Pathologists. Dr. Hayes served on the ASCO Board of Directors, and served a 3 year term as President of ASCO from 2016-2018. He is a Fellow of ASCO, a Fellow of the American College of Physicians, a past Komen Scholar, and a member of the Association of American Physicians and of the American Clinical and Climatologic Association. He has been the recipient of the ASCO Gianni Bonadonna Award in breast cancer and the Allen Lichter Visionary Leadership Award in 2021 as well as the Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research in 2023, and has received the Distinguished Alumni Award from the Indiana University Medical School (2024).

Daniel Hayes Image

Taking a Liquid Biopsy from Lab to Clinic: What It Takes to Get Ready for Prime Time

Tuesday, 7 May 2024 at 13:00

Add to Calendar ▼2024-05-07 13:00:002024-05-07 14:00:00Europe/LondonTaking a Liquid Biopsy from Lab to Clinic: What It Takes to Get Ready for Prime TimeLiquid Biopsy 2024: Technologies and Applications in Ann Arbor, MichiganAnn Arbor,

A tumor biomarker liquid biopsy test, is not just an assay for circulating proteins, tumor cells, or cell free DNA. Rather, it is a precisely developed assay that has high analytical validity and clinical utility for a specific use context. Clinical utility requires consideration of several factors and the generation of high levels of evidence that use of the assay, compared to not having the results at all, improves patient outcomes – preferably either quality or quantity of life. These issues will be discussed in the presentation.

Add to Calendar ▼2024-05-06 00:00:002024-05-07 00:00:00Europe/LondonLiquid Biopsy 2024: Technologies and ApplicationsLiquid Biopsy 2024: Technologies and Applications in Ann Arbor, MichiganAnn Arbor,